Latest News and Press Releases
Want to stay updated on the latest news?
-
RAANANA, ISRAEL, April 07, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today...
-
IRVINE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, and researchers...
-
ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham...
-
electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD
ROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the enrollment of the first eight...
-
FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701...
-
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
-
NTG Nordic Transport Group A/S – Q1 2026 Conference Call We expect to release the Q1 2026 interim results of NTG Nordic Transport Group on the evening of May 5, 2026. A webcast and conference call...
-
Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has already yielded encouraging one- and two-year data...
-
SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop...
-
Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204